FFO
CYTK icon

Fortitude Family Office’s Cytokinetics CYTK Stock Holding History

Fortitude Family Office’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.75K Buy
72
+31
+76% +$2.36K ﹤0.01% 1597
2026
Q2 		$3.49K Buy
41
+23
+128% +$1.65K ﹤0.01% 1248
2026
Q1 		$1.19K Buy
18
+13
+260% +$826 ﹤0.01% 1460
2025
Q4 		$318 Sell
5
-2
-29% -$124 ﹤0.01% 1813
2025
Q3 		$385 Hold
7
– – ﹤0.01% 1866
2025
Q2 		$231 Sell
7
-8
-53% -$278 ﹤0.01% 1947
2025
Q1 		$603 Hold
15
– – ﹤0.01% 1074
2024
Q4 		$706 Hold
15
– – ﹤0.01% 1184
2024
Q3 		$792 Hold
15
– – ﹤0.01% 1121
2024
Q2 		$813 Hold
15
– – ﹤0.01% 896
2024
Q1 		$1.05K Hold
15
– – ﹤0.01% 903
2023
Q4 		$1.25K Buy
+15
New +$543 ﹤0.01% 924

Other funds holding CYTK

MCP
Mirador Capital Partners Pleasanton, California $859M AUM 41.74% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return
Atria Investments
Atria Investments Charlotte, North Carolina $10.3B AUM 19.62% 1-Year Est. Return
State of Alaska Department of Revenue
State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
NL
NVWM LLC Yardley, Pennsylvania $533M AUM 27.53% 1-Year Est. Return
VC
Veracity Capital Atlanta, Georgia $372M AUM 32.95% 1-Year Est. Return
Gateway Investment Advisers
Gateway Investment Advisers Cincinnati, Ohio $11B AUM 34.31% 1-Year Est. Return
BCG
Breakwater Capital Group Paramus, New Jersey $844M AUM 15.36% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Fortitude Family Office's CYTK Position: Q3 2026 in Review

Fortitude Family Office increased its Cytokinetics (CYTK) stake by 76% in Q3 2026, buying an estimated $2.36K and bringing the position to 72 shares worth $4.75K. The position accounts for ﹤0.01% of the portfolio, ranked #1597.

Fortitude Family Office first reported a position in CYTK in Q4 2023 and has held it in 12 quarters since. 23 funds tracked by Wall St. Rank hold CYTK as of Q3 2026.

  • Fortitude Family Office held 72 shares of Cytokinetics worth $4.75K as of Q3 2026.
  • Fortitude Family Office bought 31 Cytokinetics shares in Q3 2026, an estimated $2.36K.
  • Cytokinetics made up ﹤0.01% of Fortitude Family Office's portfolio in Q3 2026, its #1597 holding.
  • Fortitude Family Office first reported a position in Cytokinetics in Q4 2023 and has held it in 12 quarters since.
  • 23 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2026.

Based on Fortitude Family Office's 13F filing for Q3 2026, filed 14 Oct 2026.